TranXenoGen, Inc.

Appointment of Insinger as Nominated Advisor and Broker

By mutual agreement, WestLB Panmure have resigned today as nominated advisor and broker to TranXenoGen, Inc. The Board of Directors of TranXenoGen, Inc. (the "Company") have appointed Insinger de Beaufort as the Company's nominated advisor and Insinger Townsley as the Company's broker with immediate effect.

30 June 2003

ENQUIRIES:

TranXenoGen, Inc. Tel: 001 508 936 4214

George Uveges, President and CEO Email: <u>guveges@tranxenogen.com</u>

College Hill Associates Tel: +44 (0) 7457 2020

Nicholas Nelson

Risk Warning Notice:

TranXenoGen, Inc. (symbol TXN.L) is a publicly traded biotechnology company. Its shares are quoted on the Alternative Investment Market of the London Stock Exchange. The Company is developing avian transgenic technologies for the production of high volume therapeutic proteins. TranXenoGen is a development stage company and, as such, investors should be aware that an investment in the Company involves a substantially high degree of risk.

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.